Marcel B Bally Selected Research

integrin-linked kinase

1/2015	Using Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo Model of Cancer.
5/2011	Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267.
3/2008	Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival.
1/2008	Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).
1/2006	Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.
5/2005	Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marcel B Bally Research Topics

Disease

71	Neoplasms (Cancer) 01/2022 - 04/2002
16	Breast Neoplasms (Breast Cancer) 01/2018 - 09/2003
7	Colorectal Neoplasms (Colorectal Cancer) 02/2015 - 10/2004
6	Ovarian Neoplasms (Ovarian Cancer) 12/2018 - 06/2010
6	Carcinoma (Carcinomatosis) 12/2016 - 01/2005
5	Lung Neoplasms (Lung Cancer) 01/2021 - 03/2007
5	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 05/2005
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2018
4	Glioblastoma (Glioblastoma Multiforme) 10/2018 - 03/2006
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2017 - 11/2004
4	Hypoxia (Hypoxemia) 01/2016 - 11/2004
3	Glioma (Gliomas) 10/2018 - 06/2009
3	Lymphoma (Lymphomas) 08/2017 - 11/2011
3	Hyperthermia 02/2008 - 06/2004
2	Small Cell Carcinoma 12/2018 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2013
2	Neuroblastoma 06/2017 - 01/2017
2	Disease Progression 06/2014 - 05/2011
2	Ascites 05/2011 - 02/2004
2	Weight Loss (Weight Reduction) 11/2009 - 11/2006
2	Melanoma (Melanoma, Malignant) 08/2002 - 07/2002
1	Carcinogenesis 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020
1	Brain Neoplasms (Brain Tumor) 10/2018
1	Starvation 11/2017
1	Adenocarcinoma of Lung 11/2017

Drug/Important Bio-Agent (IBA)

25	Pharmaceutical PreparationsIBA 01/2022 - 06/2004
19	Liposomes (Liposome)IBA 01/2022 - 08/2002
9	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2013 - 09/2003
8	Proteins (Proteins, Gene)FDA Link 12/2018 - 09/2003
8	Irinotecan (Camptosar)FDA LinkGeneric 02/2015 - 10/2004
7	LipidsIBA 01/2022 - 07/2002
6	Therapeutic UsesIBA 01/2022 - 04/2004
6	PlatinumIBA 12/2017 - 02/2013
6	integrin-linked kinaseIBA 01/2015 - 05/2005
5	Small Interfering RNA (siRNA)IBA 01/2021 - 03/2006
5	Fluorouracil (Carac)FDA LinkGeneric 02/2015 - 11/2008
5	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 02/2015 - 11/2004
4	Cisplatin (Platino)FDA LinkGeneric 12/2017 - 02/2008
4	Topotecan (Hycamtin)FDA LinkGeneric 06/2017 - 02/2013
4	Trastuzumab (Herceptin)FDA Link 10/2016 - 04/2004
4	QLT 0267IBA 01/2015 - 01/2006
4	liposomal doxorubicin (Doxil)FDA Link 02/2013 - 01/2005
4	Gefitinib (Iressa)FDA Link 01/2013 - 04/2004
4	Cytotoxins (Cytolysins)IBA 01/2013 - 02/2004
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2008 - 02/2004
4	Antisense OligonucleotidesIBA 03/2006 - 08/2002
3	CX 5461IBA 01/2022 - 01/2017
3	Drug CombinationsIBA 10/2021 - 04/2004
3	Carboplatin (JM8)FDA LinkGeneric 10/2018 - 01/2017
3	DNA (Deoxyribonucleic Acid)IBA 11/2017 - 11/2004
3	Biological ProductsIBA 01/2016 - 04/2002
3	Docetaxel (Taxotere)FDA Link 05/2011 - 06/2010
3	Vincristine (Oncovin)FDA LinkGeneric 04/2011 - 01/2004
3	Contrast MediaIBA 01/2007 - 06/2004
3	oblimersen (G3139)IBA 11/2004 - 07/2002
2	SolutionsIBA 01/2022 - 01/2016
2	taxaneIBA 01/2021 - 03/2014
2	ProdrugsIBA 01/2021 - 06/2010
2	AntigensIBA 01/2020 - 05/2004
2	Disulfiram (Antabuse)FDA Link 01/2018 - 01/2016
2	Clioquinol (Vioform)FDA Link 01/2018 - 12/2017
2	CopperIBA 01/2018 - 12/2017
2	Ditiocarb (Sodium Diethyldithiocarbamate)FDA Link 12/2017 - 01/2016
2	CholesterolIBA 01/2017 - 02/2008
2	Peptides (Polypeptides)IBA 12/2016 - 05/2004
2	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 07/2011
2	LactonesIBA 02/2015 - 02/2008
2	LuciferasesIBA 01/2015 - 05/2011
2	Lipid NanoparticlesIBA 12/2014 - 11/2011
2	Estrogen ReceptorsIBA 06/2014 - 04/2004
2	ErbB Receptors (EGF Receptor)IBA 12/2007 - 04/2004
2	Vinorelbine (Navelbine)FDA LinkGeneric 03/2007 - 11/2004
2	ManganeseIBA 01/2007 - 11/2006
2	Antineoplastic Agents (Antineoplastics)IBA 11/2006 - 04/2002
2	SuspensionsIBA 11/2004 - 04/2004
2	OligodeoxyribonucleotidesIBA 09/2003 - 07/2002
1	Dimyristoylphosphatidylcholine (DMPC)IBA 01/2022
1	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2021
1	Daunorubicin (Cerubidine)FDA LinkGeneric 10/2021
1	alvocidib (flavopiridol)IBA 10/2021
1	Androgen Receptors (Androgen Receptor)IBA 01/2021
1	CarcinogensIBA 01/2021
1	QuercetinIBA 01/2020
1	OTS964IBA 12/2019
1	Protein Kinases (Protein Kinase)IBA 12/2019
1	Histone Deacetylase InhibitorsIBA 12/2018
1	Histones (Histone)IBA 12/2018
1	quisinostatIBA 12/2018
1	Antifungal AgentsIBA 01/2018
1	LigandsIBA 12/2017
1	Oxyquinoline (8 Hydroxyquinoline)FDA Link 12/2017
1	plumbaginIBA 12/2017
1	pyrithioneIBA 12/2017
1	Biomarkers (Surrogate Marker)IBA 11/2017

Therapy/Procedure

16	Therapeutics 09/2018 - 04/2002
11	Drug Therapy (Chemotherapy) 10/2018 - 04/2002
4	Aftercare (After-Treatment) 01/2015 - 06/2004
3	Immunotherapy 06/2019 - 05/2004
3	Radiotherapy 06/2017 - 08/2006